Kawasaki Disease (KD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 Kawasaki Disease (KD) Market Outlook

Thelansis’s “Kawasaki Disease (KD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Kawasaki Disease (KD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Kawasaki Disease (KD) Overview

Kawasaki disease (KD), also referred to as mucocutaneous lymph node syndrome, is an acute medium vessel vasculitis characterized by a preference for the coronary arteries. It is the primary cause of acquired heart disease in developed nations and is progressively surpassing rheumatic heart disease in developing countries. The precise etiology of Kawasaki disease remains unknown, but it may be associated with an airborne or waterborne pathogen. Typically, affected children initially manifest with a high fever that exhibits a remittent pattern and lasts for approximately one to two weeks without treatment. In some instances, the fever may persist for up to three to four weeks. Additional distinctive features include bilateral conjunctivitis (inflammation of the whites of the eyes), inflammation of the mucous membranes of the mouth and throat leading to dry, red, cracked lips and a strawberry-red tongue, cervical lymphadenopathy (swelling of lymph nodes in the neck), redness and swelling of the hands and feet, and a reddish rash that typically affects the trunk and often extends to the groin area. The prognosis of Kawasaki disease depends on the severity of cardiac involvement. Furthermore, the prognosis is more favorable for children diagnosed between the ages of 6 months and 9 years compared to those younger or older, possibly due to earlier diagnosis following the presentation of classic symptoms. Recurrence is infrequent but more likely in younger children who experienced cardiac complications during the initial episode of the disease. All deaths related to Kawasaki disease are primarily attributed to cardiac complications and typically occur within 15-45 days from the onset of fever. The disease can lead to the formation of aneurysms, heart failure, myocardial infarction (MI), myocarditis, valvulitis, pericarditis with pericardial effusion, and rupture of the coronary arteries resulting in hemopericardium and sudden death. Approximately 9% of patients experience acute phase cardiac complications, while about 3% develop cardiac sequelae. Patients with Kawasaki disease frequently experience myocardial infarctions during sleep or rest, suggesting a potential etiology involving coronary vasospasm. Myocardial inflammation is observed in 50 to 70% of patients during the acute phase of the disease, raising concerns about the long-term impact of Kawasaki disease on cardiac function. Kawasaki disease is most commonly observed in children under five and can manifest at any age, including adulthood.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Kawasaki Disease (KD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034